The publications contained in this archive section are provided for historical purposes only. The views expressed in the publications are those of their respective authors and do not reflect the views of TME Pharma. TME Pharma disavows any obligation to update or correct the information contained in these publications.
Dual inhibition of postradiogenic angio-vasculogenesis in glioblastoma: Results of the phase 1/2 GLORIA trial.
Giordano FA, Layer JP, Friker LF, Turiello R, Zeyen T, Pregler B, Potthoff A-L, Mirallas O, Kebir S, Renovanz M, Hambsch P, Pietsch T, Gkika E, Schneider M, Grauer O, Tabatabai G, Glas M, Seidel C, Herrlinger U, Hölzel M.
ESMO 2024 September 15.
Presentation
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial.
Giordano FA, Layer JP, Leonardelli S, Friker LF, Turiello R, Corvino D, Zeyen T, Schaub C, Müller W, Sperk E, Schmeel LC, Sahm K, Oster C, Kebir S, Hambsch P, Pietsch T, Bisdas S, Platten M, Glas M, Seidel C, Herrlinger U, Hölzel M.
Nat Commun. 2024, 15(1), 2410.
read abstract on pubmed.gov
Interim data on dual inhibition of post- radiogenic angio-vasculogenesis by olaptesed pegol (NOX-A12) and bevacizumab in glioblastoma from the first expansion arm of the Phase 1/2 GLORIA trial.
Giordano FA, Layer JP, Leonardelli S, Friker LL, Schaub C, Zeyen T, Sperk E, Mueller W, Sperk E, Hambsch P, Oster C, Grau F, Paech D, Müller W, Pietsch T, Schmeel LC, Grauer O, Renovanz M, Tabatabai G, Kebir S, Bisdas S, Güresir E, Glas M, Seidel C, Hölzel M, Herrlinger U.
SNO 2023 November 18.
Poster Presentation
Potential predictive biomarker for response to radiotherapy and CXCL12-inhibition in glioblastoma in the phase I/II GLORIA trial.
Giordano FA, Layer JP, Leonardelli S, Friker LL, Turiello R, Corvino D, Zeyen T, Schaub C, Mueller W, Sperk E, Schmeel LC, Sahm K, Kebir S, Hambsch P, Pietsch T, Bisdas S, Glas M, Seidel C, Herrlinger U, Hölzel M.
ASCO 2023 June 03.
Poster Presentation
The prospect of tumor microenvironment-modulating therapeutical strategies.
Eulberg D, Frömming A, Lapid K, Mangasarian A, Barak A.
Front Oncol 2022, 12, 1070243.
read article on nih.gov
Dual inhibition of post-radiogenic angio- vasculogenesis by olaptesed pegol (NOX-A12) and bevacizumab in glioblastoma – Interim data from the first expansion arm of the German Phase 1/2 GLORIA trial.
Giordano FA, Layer JP, Leonardelli S, Friker LL, Schaub C, Turiello R, Sperk E, Mildenberger I, Grau F, Paech D, Pietsch T, Mueller W, Grauer O, Renovanz M, Tabatabai G, Kebir S, Glas M, Bisdas S, Hambsch P, Seidel C, Hölzel M, Herrlinger U.
SNO 2022 November 18.
Poster Presentation
Radiotherapy and olaptesed pegol (NOX-A12) in partially resected or biopsy-only MGMT unmethylated glioblastoma: Interim data from the German multicenter Phase 1/2 GLORIA trial.
Giordano FA, Layer JP, Leonardelli S, Friker LL, Seidel C, Schaub C, Turiello R, Sperk E, Grau F, Paech D, Link B, Mueller W, Tabatabai G, Sahm K, Kebir S, Pietsch T, Glas M, Bisdas S, Herrlinger U, Hölzel M.
ASCO 2022 June.
Poster Presentation
CXCL12 inhibition in MGMT unmethylated glioblastoma – Results of an early proof-of-concept assessment in the multicentric phase I/II GLORIA trial (NCT04121455).
Giordano FA, Layer JP, Leonardelli S, Friker L, Seidel C, Zeyen T, Schaub C, Sperk E, Grau F, Paech D, Radbruch A, Sahm K, Kebir S, Hambsch P, Pietsch T, Glas M, Bisdas S, Hölzel M, Herrlinge U.
SNO 2021 November.
Slide Presentation
Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects.
Suarez-Carmona M, Williams A, Schreiber J, Hohmann N, Pruefer U, Krauss J, Jäger D, Frömming A, Beyer D, Eulberg D, Jungelius JU, Baumann M, Mangasarian A, Halama N.
J Immunother Cancer 2021, 9, e002505.
read article on bmj.com
Final Top-Line Data: CXCL12 inhibitor NOX-A12 and pembrolizumab in microsatellite-stable, metastatic colorectal or pancreatic cancer.
Halama N, Williams A, Suarez-Carmona M, Schreiber J, Hohmann N, Prüfer U, Krauss J, Jäger D, Frömming A, Beyer D, Eulberg D, Jungnelius JU, Mangasarian A.
ESMO 2020 (09), Poster Presentation.
Poster
Clinical outcome and safety in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 in combination with PD-1 checkpoint inhibitor pembrolizumab.
Halama N, Prüfer U, Frömming A, Beyer D, Eulberg D, Jungnelius JU, Mangasarian A.
AACR 2019 (04), Poster Presentation.
Poster
Correlation of clinical benefit with target neutralization and immune response in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 in combination with PD-1 checkpoint inhibitor pembrolizumab.
Halama N, Prüfer U, Frömming A, Beyer D, Eulberg D, Jungnelius JU, Mangasarian A.
ESMO 2018 (11), Poster Presentation.
Poster
Evaluation of tumor biomarkers in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 and preliminary safety in combination with PD-1 checkpoint inhibitor pembrolizumab.
Halama N, Prüfer U, Frömming A, Beyer D, Eulberg D, Jungnelius JU, Mangasarian A.
CRI-CIMT-EATI-AACR 2018 (09), Poster Presentation.
Poster
Dynamic cellular phynotyping defines specific mobilization mechanisms of human hematopoietic stem and progenitor cells induced by SDF1α versus synthetic agents.
Monzel C, Becker AS, Saffrich R, Wuchter P, Eckstein V, Ho AD, Tanaka M.
Sci Rep. 2018, 8(1), 1841.
read abstract on pubmed.gov
Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition.
Weisberg EL, Sattler M, Azab AK, Eulberg D, Kruschinski A, Manley PW, Stone R, Griffin JD.
Oncotarget. 2017, 8(66), 109973-84.
read abstract on pubmed.gov
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib – dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.
Ludwig H, Weisel K, Petrucci MT, Leleu X, Cafro AM, Garderet L, Leitgeb C, Foa R, Greil R, Yakoub-Agha I, Zboralski D, Vauléon S, Dümmler T, Beyer D, Kruschinski A, Riecke K, Baumann M, Engelhardt M.
Leukemia. 2017, 31, 997-1000.
read article on pubmed.gov
SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI.
Deng L, Stafford JH, Liu SC, Chernikova SB, Merchant M, Recht L, Martin Brown J.
Neoplasia. 2017, 19(1), 1-7.
read abstract on pubmed.gov
Increasing tumor-infiltrating T cells through inhibition of CXCL12 with NOX-A12 synergizes with PD-1 blockade.
Zboralski D, Hoehlig K, Eulberg D, Froemming A, Vater A
Cancer Immunol Res. 2017.
read article on aacrjournals.org
CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.
Waldschmidt JM, Simon A, Wider D, Müller SJ, Follo M, Ihorst G, Decker S, Lorenz J, Chatterjee M, Azab AK, Duyster J, Wäsch R, Engelhardt M.
Br J Haematol. 2017, 179(1), 36.
read abstract on pubmed.gov
Systemic Monocyte Chemotactic Protein-1 Inhibition Modifies Renal Macrophages and Restores Glomerular Endothelial Glycocalyx and Barrier Function in Diabetic Nephropathy.
Boels MGS, Koudijs A, Avramut MC, Sol WMPJ, Wang G, van Oeveren-Rietdijk AM, van Zonneveld AJ, de Boer HC, van der Vlag J, van Kooten C, Eulberg D, van den Berg BM, IJpelaar DHT, Rabelink TJ.
Am J Pathol. 2017.
read article on amjpathol.org